[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuvectis Pharma Inc (NVCT)

Nuvectis Pharma Inc (NVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 497,362
  • Shares Outstanding, K 26,526
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,440 K
  • EBIT $ -28 M
  • EBITDA $ -28 M
  • 60-Month Beta -0.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 37.36

Options Overview Details

View History
  • Implied Volatility 191.59% (-6.89%)
  • Historical Volatility 177.96%
  • IV Percentile 32%
  • IV Rank 23.71%
  • IV High 684.74% on 11/07/25
  • IV Low 38.36% on 09/05/25
  • Expected Move (DTE 8) 1.70 (8.85%)
  • Put/Call Vol Ratio 5.00
  • Today's Volume 12
  • Volume Avg (30-Day) 467
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 14,301
  • Open Int (30-Day) 12,734
  • Expected Range 17.50 to 20.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.25
  • Number of Estimates 2
  • High Estimate $-0.24
  • Low Estimate $-0.25
  • Prior Year $-0.30
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.67 +97.10%
on 06/10/26
29.27 -34.89%
on 06/29/26
+9.26 (+94.49%)
since 06/09/26
3-Month
8.08 +135.89%
on 04/10/26
29.27 -34.89%
on 06/29/26
+10.90 (+133.58%)
since 04/09/26
52-Week
5.55 +243.42%
on 11/07/25
29.27 -34.89%
on 06/29/26
+10.98 (+135.89%)
since 07/09/25

Most Recent Stories

More News
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment...

NVCT : 19.03 (+1.47%)
Nuvectis Pharma Announces Proposed Public Offering of Common Stock

FORT LEE, NJ, June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment...

NVCT : 19.03 (+1.47%)
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor B inhibitor (CFBi...

NVCT : 19.03 (+1.47%)
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...

NVCT : 19.03 (+1.47%)
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

NXP900 Phase 1b clinical program continues to enroll patients at select sites in the US NXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting”...

NVCT : 19.03 (+1.47%)
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...

NVCT : 19.03 (+1.47%)
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...

NVCT : 19.03 (+1.47%)
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Fort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the...

NVCT : 19.03 (+1.47%)
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Fort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision...

NVCT : 19.03 (+1.47%)
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The...

NVCT : 19.03 (+1.47%)

Business Summary

Nuvectis Pharma Inc. is a biopharmaceutical company. It focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. Nuvectis Pharma Inc. is based in Fort Lee, NJ.

See More

Key Turning Points

3rd Resistance Point 20.31
2nd Resistance Point 19.80
1st Resistance Point 19.28
Last Price 19.03
1st Support Level 18.25
2nd Support Level 17.74
3rd Support Level 17.22

See More

52-Week High 29.27
Fibonacci 61.8% 20.21
Last Price 19.03
Fibonacci 50% 17.41
Fibonacci 38.2% 14.61
52-Week Low 5.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.